Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been given an average rating of “Moderate Buy” by the seven research firms that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $53.40.

COLL has been the subject of a number of research analyst reports. Zacks Research lowered Collegium Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a report on Tuesday, February 10th. Weiss Ratings downgraded Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, March 5th. Barclays decreased their target price on Collegium Pharmaceutical from $58.00 to $56.00 and set an “overweight” rating for the company in a research report on Friday, January 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $56.00 price target (up from $54.00) on shares of Collegium Pharmaceutical in a report on Thursday, March 19th.

Insider Activity at Collegium Pharmaceutical

In related news, EVP David Dieter sold 13,976 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $34.92, for a total transaction of $488,041.92. Following the transaction, the executive vice president owned 77,071 shares in the company, valued at $2,691,319.32. This represents a 15.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Scott Dreyer sold 49,976 shares of the firm’s stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $40.41, for a total transaction of $2,019,530.16. Following the completion of the sale, the executive vice president owned 71,770 shares in the company, valued at $2,900,225.70. This represents a 41.05% decrease in their position. The SEC filing for this sale provides additional information. 2.51% of the stock is owned by insiders.

Institutional Trading of Collegium Pharmaceutical

A number of hedge funds have recently bought and sold shares of COLL. Rubric Capital Management LP boosted its position in Collegium Pharmaceutical by 5.3% in the second quarter. Rubric Capital Management LP now owns 3,157,743 shares of the specialty pharmaceutical company’s stock worth $93,374,000 after purchasing an additional 157,743 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock valued at $104,465,000 after purchasing an additional 29,876 shares during the last quarter. Renaissance Technologies LLC lifted its stake in shares of Collegium Pharmaceutical by 1.1% in the 4th quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after purchasing an additional 18,160 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Collegium Pharmaceutical by 59.1% in the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of Collegium Pharmaceutical by 0.3% in the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock worth $60,823,000 after buying an additional 3,891 shares during the last quarter.

Collegium Pharmaceutical Trading Down 2.8%

Collegium Pharmaceutical stock opened at $32.31 on Friday. The company has a current ratio of 1.57, a quick ratio of 1.48 and a debt-to-equity ratio of 2.59. The business’s fifty day simple moving average is $40.77 and its two-hundred day simple moving average is $41.54. Collegium Pharmaceutical has a 12 month low of $23.23 and a 12 month high of $50.79. The company has a market capitalization of $1.03 billion, a price-to-earnings ratio of 18.89 and a beta of 0.77.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, February 26th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, missing the consensus estimate of $2.20 by ($0.16). Collegium Pharmaceutical had a net margin of 8.05% and a return on equity of 98.65%. The firm had revenue of $205.45 million for the quarter, compared to analysts’ expectations of $206.36 million. During the same period last year, the company posted $1.77 earnings per share. The business’s revenue for the quarter was up 12.9% compared to the same quarter last year. As a group, equities analysts predict that Collegium Pharmaceutical will post 5.62 earnings per share for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.